Induced pluripotent stem cell technologies for tissue engineering

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Induced pluripotent stem cells (iPSCs) were first established by delivering the four factors c-Myc/Klf4/Oct4/Sox2 or Lin28/Nanog/Oct4/Sox2 into dermal fibroblasts via a viral vector-based approach. While many aspects of iPSCs require investigation concerning their clinical safety, utilising iPSCs for cell therapy is anticipated to take place in the future. This chapter focuses on cell-based tissue regeneration and generation of patient-specific iPSCs to study disease mechanisms. It provides an overview of current progress in this area, particularly emphasising neurogenesis. Additionally, utilising iPSCs as a tool for studying genetics and disease mechanisms are also be reviewed. Osteogenic differentiation of iPSCs for bone tissue regeneration has been reported using scaffolds such as macro-channeled polycaprolactone scaffolds, polyethersulfone nanofibrous scaffolds and fibrin or hydroxyapatite/p-tricalcium phosphate. iPSC-derived cardiomyocytes have been engrafted successfully into the hearts of experimental animals and used to improve cardiac function after ischemic cardiomyopathy in a porcine model.

Original languageEnglish (US)
Title of host publicationTissue Engineering and Regeneration in Dentistry
Subtitle of host publicationCurrent Strategies
PublisherWiley-Blackwell
Pages1-19
Number of pages19
ISBN (Electronic)9781119282181
ISBN (Print)9781118741108
DOIs
StatePublished - Nov 1 2016

Fingerprint

Induced Pluripotent Stem Cells
Tissue Engineering
Technology
Inborn Genetic Diseases
Bone Regeneration
Neurogenesis
Durapatite
Cell- and Tissue-Based Therapy
Fibrin
Cardiomyopathies
Cardiac Myocytes
Regeneration
Swine
Fibroblasts
Safety
Bone and Bones
Skin

All Science Journal Classification (ASJC) codes

  • Dentistry(all)

Cite this

Huang, G., El Ayachi, I., & Zou, X. Y. (2016). Induced pluripotent stem cell technologies for tissue engineering. In Tissue Engineering and Regeneration in Dentistry: Current Strategies (pp. 1-19). Wiley-Blackwell. https://doi.org/10.1002/9781119282181.ch1

Induced pluripotent stem cell technologies for tissue engineering. / Huang, George; El Ayachi, Ikbale; Zou, Xiao Ying.

Tissue Engineering and Regeneration in Dentistry: Current Strategies. Wiley-Blackwell, 2016. p. 1-19.

Research output: Chapter in Book/Report/Conference proceedingChapter

Huang, G, El Ayachi, I & Zou, XY 2016, Induced pluripotent stem cell technologies for tissue engineering. in Tissue Engineering and Regeneration in Dentistry: Current Strategies. Wiley-Blackwell, pp. 1-19. https://doi.org/10.1002/9781119282181.ch1
Huang G, El Ayachi I, Zou XY. Induced pluripotent stem cell technologies for tissue engineering. In Tissue Engineering and Regeneration in Dentistry: Current Strategies. Wiley-Blackwell. 2016. p. 1-19 https://doi.org/10.1002/9781119282181.ch1
Huang, George ; El Ayachi, Ikbale ; Zou, Xiao Ying. / Induced pluripotent stem cell technologies for tissue engineering. Tissue Engineering and Regeneration in Dentistry: Current Strategies. Wiley-Blackwell, 2016. pp. 1-19
@inbook{2a8f4b7b37f14b759ed697dc2003f23d,
title = "Induced pluripotent stem cell technologies for tissue engineering",
abstract = "Induced pluripotent stem cells (iPSCs) were first established by delivering the four factors c-Myc/Klf4/Oct4/Sox2 or Lin28/Nanog/Oct4/Sox2 into dermal fibroblasts via a viral vector-based approach. While many aspects of iPSCs require investigation concerning their clinical safety, utilising iPSCs for cell therapy is anticipated to take place in the future. This chapter focuses on cell-based tissue regeneration and generation of patient-specific iPSCs to study disease mechanisms. It provides an overview of current progress in this area, particularly emphasising neurogenesis. Additionally, utilising iPSCs as a tool for studying genetics and disease mechanisms are also be reviewed. Osteogenic differentiation of iPSCs for bone tissue regeneration has been reported using scaffolds such as macro-channeled polycaprolactone scaffolds, polyethersulfone nanofibrous scaffolds and fibrin or hydroxyapatite/p-tricalcium phosphate. iPSC-derived cardiomyocytes have been engrafted successfully into the hearts of experimental animals and used to improve cardiac function after ischemic cardiomyopathy in a porcine model.",
author = "George Huang and {El Ayachi}, Ikbale and Zou, {Xiao Ying}",
year = "2016",
month = "11",
day = "1",
doi = "10.1002/9781119282181.ch1",
language = "English (US)",
isbn = "9781118741108",
pages = "1--19",
booktitle = "Tissue Engineering and Regeneration in Dentistry",
publisher = "Wiley-Blackwell",
address = "United Kingdom",

}

TY - CHAP

T1 - Induced pluripotent stem cell technologies for tissue engineering

AU - Huang, George

AU - El Ayachi, Ikbale

AU - Zou, Xiao Ying

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Induced pluripotent stem cells (iPSCs) were first established by delivering the four factors c-Myc/Klf4/Oct4/Sox2 or Lin28/Nanog/Oct4/Sox2 into dermal fibroblasts via a viral vector-based approach. While many aspects of iPSCs require investigation concerning their clinical safety, utilising iPSCs for cell therapy is anticipated to take place in the future. This chapter focuses on cell-based tissue regeneration and generation of patient-specific iPSCs to study disease mechanisms. It provides an overview of current progress in this area, particularly emphasising neurogenesis. Additionally, utilising iPSCs as a tool for studying genetics and disease mechanisms are also be reviewed. Osteogenic differentiation of iPSCs for bone tissue regeneration has been reported using scaffolds such as macro-channeled polycaprolactone scaffolds, polyethersulfone nanofibrous scaffolds and fibrin or hydroxyapatite/p-tricalcium phosphate. iPSC-derived cardiomyocytes have been engrafted successfully into the hearts of experimental animals and used to improve cardiac function after ischemic cardiomyopathy in a porcine model.

AB - Induced pluripotent stem cells (iPSCs) were first established by delivering the four factors c-Myc/Klf4/Oct4/Sox2 or Lin28/Nanog/Oct4/Sox2 into dermal fibroblasts via a viral vector-based approach. While many aspects of iPSCs require investigation concerning their clinical safety, utilising iPSCs for cell therapy is anticipated to take place in the future. This chapter focuses on cell-based tissue regeneration and generation of patient-specific iPSCs to study disease mechanisms. It provides an overview of current progress in this area, particularly emphasising neurogenesis. Additionally, utilising iPSCs as a tool for studying genetics and disease mechanisms are also be reviewed. Osteogenic differentiation of iPSCs for bone tissue regeneration has been reported using scaffolds such as macro-channeled polycaprolactone scaffolds, polyethersulfone nanofibrous scaffolds and fibrin or hydroxyapatite/p-tricalcium phosphate. iPSC-derived cardiomyocytes have been engrafted successfully into the hearts of experimental animals and used to improve cardiac function after ischemic cardiomyopathy in a porcine model.

UR - http://www.scopus.com/inward/record.url?scp=85019816637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019816637&partnerID=8YFLogxK

U2 - 10.1002/9781119282181.ch1

DO - 10.1002/9781119282181.ch1

M3 - Chapter

SN - 9781118741108

SP - 1

EP - 19

BT - Tissue Engineering and Regeneration in Dentistry

PB - Wiley-Blackwell

ER -